Cure8 research brief
People with UC have lower baseline gut microbial diversity and slower recovery after PEG bowel preparation; improving recovery of beneficial microbes could matter for symptom stability and gut health. This study suggests post-procedure probiotics speed microbiota recovery markers, particularly in UC.
Adults with ulcerative colitis undergoing colonoscopy, gastroenterologists and endoscopy teams, clinical researchers studying the gut microbiome, and patients interested in probiotics or microbiome-directed recovery after bowel prep.
The study enrolled healthy volunteers and people with UC who underwent colonoscopy with PEG-based bowel preparation. Participants were randomized to probiotic supplementation vs no probiotic for 28 days after the procedure.
Stool samples were collected at baseline and days 2, 14, and 28 and analyzed by 16S rRNA sequencing to assess diversity, composition, and predicted functions. Results reported in the abstract: PEG bowel prep caused a drop in microbial diversity in everyone, with recovery by day 28 in healthy controls but slower recovery in people with UC.
Probiotics were associated with modest improvement in microbial recovery in healthy participants and larger improvements in Shannon diversity and evenness in UC patients.
The probiotic group showed enrichment of short-chain fatty acid–producing taxa (Faecalibacterium, Blautia, Lachnospiraceae) and reductions in Proteobacteria and Fusobacteria; some predicted metabolic pathways suppressed after prep partially recovered over time.
Practical takeaways: The trial suggests probiotics after colonoscopy may help microbiota recovery—especially for people with UC—but the abstract reports microbial sequencing markers and predicted pathways rather than clinical outcomes. Discussing probiotic use with a clinician is reasonable if microbiota recovery is a concern after colonoscopy.
This record is an abstract of a single-center randomized trial reporting microbiome sequencing and predicted functional changes; it does not report clinical outcomes. Probiotic formulations, dosing, and regulatory status vary—benefits seen in sequencing measures here do not necessarily translate to symptom improvement.
Full paper review is needed for details on the probiotic product, randomization, and statistical analyses.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...
AI tools could make objective disease assessment faster and more consistent, help detect inflammation beyond what symptoms suggest, and ultimately support more personalized treatment choices for people with Crohn’s...
Researchers are exploring ways to prioritize who needs colonoscopy sooner; adding TCM features to prediction models might change triage performance. Patients and clinicians interested in pre-endoscopic risk tools or...
